An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin

Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Yuichi Tanabe, Takeaki Satoh, Toshihiro Maruyama, Makoto Nakamuta, Kazuhiro Kotoh, Koichi Azuma, Kazufumi Dohmen, Shinji Shimoda, Jun Hayashi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The aim of this large-scale analysis was to assess the effect of 48-week pegylated interferon (PEGIFN) a-2b and ribavirin (RBV) therapy on virological relapse by patients infected with hepatitis C virus (HCV) genotype 1. The relationship between virological relapse and the dose of PEG-IFNa-2b and RBV was investigated in 619 patients who had once cleared HCV RNA during PEGIFNa- 2b and RBV treatment for 48 weeks. The overall virological relapse rate was 34.1% (211 of 619). The relapse rate was 59.5% (22 of 37) for patients who received <6 mg/kg/day of RBV, even if a sufficient dose of PEGIFNa- 2b (C1.5 lg/kg/day) was received. In contrast, the relapse rate was 28.1% (16 of 57) for patients who received C12 mg/kg/day of RBV, irrespective of the PEG-IFNa-2b dose. The relapse rates were significantly increased with the reduction of the RBV dose for both PEG-IFNa-2b doses of C1.2 and ≥1.2 lg/kg/week (P<0.0001 and P = 0.0006, respectively). Moreover, the relapse rate was 41.2% (35 of 85) for patients with an early virological response (EVR) who received<6 mg/kg/day of RBV. The relapse rates were significantly increased with the reduction of the RBV dose in both those patients with an EVR and those with a late virological response (P = 0.0006 and P = 0.0088, respectively). To summarize, for HCV genotype 1 patients treated with PEG-IFNa-2b and RBV, the virological relapse of HCV was RBV dose-dependent, irrespective of the dose of PEG-IFNa or the effect of early viral kinetics.

Original languageEnglish
Pages (from-to)689-697
Number of pages9
JournalJournal of Infection and Chemotherapy
Volume18
Issue number5
DOIs
Publication statusPublished - Jan 1 2012

Fingerprint

Ribavirin
Chronic Hepatitis C
Recurrence
Hepacivirus
Genotype
peginterferon alfa-2b
Interferons
RNA

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. / Ogawa, Eiichi; Furusyo, Norihiro; Kajiwara, Eiji; Takahashi, Kazuhiro; Nomura, Hideyuki; Tanabe, Yuichi; Satoh, Takeaki; Maruyama, Toshihiro; Nakamuta, Makoto; Kotoh, Kazuhiro; Azuma, Koichi; Dohmen, Kazufumi; Shimoda, Shinji; Hayashi, Jun.

In: Journal of Infection and Chemotherapy, Vol. 18, No. 5, 01.01.2012, p. 689-697.

Research output: Contribution to journalArticle

Ogawa, E, Furusyo, N, Kajiwara, E, Takahashi, K, Nomura, H, Tanabe, Y, Satoh, T, Maruyama, T, Nakamuta, M, Kotoh, K, Azuma, K, Dohmen, K, Shimoda, S & Hayashi, J 2012, 'An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin', Journal of Infection and Chemotherapy, vol. 18, no. 5, pp. 689-697. https://doi.org/10.1007/s10156-012-0396-5
Ogawa, Eiichi ; Furusyo, Norihiro ; Kajiwara, Eiji ; Takahashi, Kazuhiro ; Nomura, Hideyuki ; Tanabe, Yuichi ; Satoh, Takeaki ; Maruyama, Toshihiro ; Nakamuta, Makoto ; Kotoh, Kazuhiro ; Azuma, Koichi ; Dohmen, Kazufumi ; Shimoda, Shinji ; Hayashi, Jun. / An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. In: Journal of Infection and Chemotherapy. 2012 ; Vol. 18, No. 5. pp. 689-697.
@article{fc8457f7aa7b4861bb10a8c8e0fc2a7f,
title = "An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin",
abstract = "The aim of this large-scale analysis was to assess the effect of 48-week pegylated interferon (PEGIFN) a-2b and ribavirin (RBV) therapy on virological relapse by patients infected with hepatitis C virus (HCV) genotype 1. The relationship between virological relapse and the dose of PEG-IFNa-2b and RBV was investigated in 619 patients who had once cleared HCV RNA during PEGIFNa- 2b and RBV treatment for 48 weeks. The overall virological relapse rate was 34.1{\%} (211 of 619). The relapse rate was 59.5{\%} (22 of 37) for patients who received <6 mg/kg/day of RBV, even if a sufficient dose of PEGIFNa- 2b (C1.5 lg/kg/day) was received. In contrast, the relapse rate was 28.1{\%} (16 of 57) for patients who received C12 mg/kg/day of RBV, irrespective of the PEG-IFNa-2b dose. The relapse rates were significantly increased with the reduction of the RBV dose for both PEG-IFNa-2b doses of C1.2 and ≥1.2 lg/kg/week (P<0.0001 and P = 0.0006, respectively). Moreover, the relapse rate was 41.2{\%} (35 of 85) for patients with an early virological response (EVR) who received<6 mg/kg/day of RBV. The relapse rates were significantly increased with the reduction of the RBV dose in both those patients with an EVR and those with a late virological response (P = 0.0006 and P = 0.0088, respectively). To summarize, for HCV genotype 1 patients treated with PEG-IFNa-2b and RBV, the virological relapse of HCV was RBV dose-dependent, irrespective of the dose of PEG-IFNa or the effect of early viral kinetics.",
author = "Eiichi Ogawa and Norihiro Furusyo and Eiji Kajiwara and Kazuhiro Takahashi and Hideyuki Nomura and Yuichi Tanabe and Takeaki Satoh and Toshihiro Maruyama and Makoto Nakamuta and Kazuhiro Kotoh and Koichi Azuma and Kazufumi Dohmen and Shinji Shimoda and Jun Hayashi",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/s10156-012-0396-5",
language = "English",
volume = "18",
pages = "689--697",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin

AU - Ogawa, Eiichi

AU - Furusyo, Norihiro

AU - Kajiwara, Eiji

AU - Takahashi, Kazuhiro

AU - Nomura, Hideyuki

AU - Tanabe, Yuichi

AU - Satoh, Takeaki

AU - Maruyama, Toshihiro

AU - Nakamuta, Makoto

AU - Kotoh, Kazuhiro

AU - Azuma, Koichi

AU - Dohmen, Kazufumi

AU - Shimoda, Shinji

AU - Hayashi, Jun

PY - 2012/1/1

Y1 - 2012/1/1

N2 - The aim of this large-scale analysis was to assess the effect of 48-week pegylated interferon (PEGIFN) a-2b and ribavirin (RBV) therapy on virological relapse by patients infected with hepatitis C virus (HCV) genotype 1. The relationship between virological relapse and the dose of PEG-IFNa-2b and RBV was investigated in 619 patients who had once cleared HCV RNA during PEGIFNa- 2b and RBV treatment for 48 weeks. The overall virological relapse rate was 34.1% (211 of 619). The relapse rate was 59.5% (22 of 37) for patients who received <6 mg/kg/day of RBV, even if a sufficient dose of PEGIFNa- 2b (C1.5 lg/kg/day) was received. In contrast, the relapse rate was 28.1% (16 of 57) for patients who received C12 mg/kg/day of RBV, irrespective of the PEG-IFNa-2b dose. The relapse rates were significantly increased with the reduction of the RBV dose for both PEG-IFNa-2b doses of C1.2 and ≥1.2 lg/kg/week (P<0.0001 and P = 0.0006, respectively). Moreover, the relapse rate was 41.2% (35 of 85) for patients with an early virological response (EVR) who received<6 mg/kg/day of RBV. The relapse rates were significantly increased with the reduction of the RBV dose in both those patients with an EVR and those with a late virological response (P = 0.0006 and P = 0.0088, respectively). To summarize, for HCV genotype 1 patients treated with PEG-IFNa-2b and RBV, the virological relapse of HCV was RBV dose-dependent, irrespective of the dose of PEG-IFNa or the effect of early viral kinetics.

AB - The aim of this large-scale analysis was to assess the effect of 48-week pegylated interferon (PEGIFN) a-2b and ribavirin (RBV) therapy on virological relapse by patients infected with hepatitis C virus (HCV) genotype 1. The relationship between virological relapse and the dose of PEG-IFNa-2b and RBV was investigated in 619 patients who had once cleared HCV RNA during PEGIFNa- 2b and RBV treatment for 48 weeks. The overall virological relapse rate was 34.1% (211 of 619). The relapse rate was 59.5% (22 of 37) for patients who received <6 mg/kg/day of RBV, even if a sufficient dose of PEGIFNa- 2b (C1.5 lg/kg/day) was received. In contrast, the relapse rate was 28.1% (16 of 57) for patients who received C12 mg/kg/day of RBV, irrespective of the PEG-IFNa-2b dose. The relapse rates were significantly increased with the reduction of the RBV dose for both PEG-IFNa-2b doses of C1.2 and ≥1.2 lg/kg/week (P<0.0001 and P = 0.0006, respectively). Moreover, the relapse rate was 41.2% (35 of 85) for patients with an early virological response (EVR) who received<6 mg/kg/day of RBV. The relapse rates were significantly increased with the reduction of the RBV dose in both those patients with an EVR and those with a late virological response (P = 0.0006 and P = 0.0088, respectively). To summarize, for HCV genotype 1 patients treated with PEG-IFNa-2b and RBV, the virological relapse of HCV was RBV dose-dependent, irrespective of the dose of PEG-IFNa or the effect of early viral kinetics.

UR - http://www.scopus.com/inward/record.url?scp=84871370458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871370458&partnerID=8YFLogxK

U2 - 10.1007/s10156-012-0396-5

DO - 10.1007/s10156-012-0396-5

M3 - Article

VL - 18

SP - 689

EP - 697

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 5

ER -